Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

This study aimed to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK)/ pharmacodynamics (PD) of ICP-B02 in relapsed/refractory (R/R) B-cell non-hodgkin lymphoma (NHL).